{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:20:26Z","timestamp":1764174026780,"version":"3.37.3"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ecco-jccjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Crohn's and Colitis"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.crohns.2013.08.004","type":"journal-article","created":{"date-parts":[[2013,8,29]],"date-time":"2013-08-29T20:30:34Z","timestamp":1377808234000},"page":"161-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Tolerability of one hour 10mg\/kg infliximab infusions in inflammatory bowel diseases: A prospective multicenter cohort study"],"prefix":"10.1093","volume":"8","author":[{"given":"Abdenour","family":"Babouri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Roblin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"H\u00e9buterne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc-Andr\u00e9","family":"Bigard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"10.1016\/j.crohns.2013.08.004_bb0005","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2013.08.004_bb0010","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2013.08.004_bb0015","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.crohns.2013.08.004_bb0020","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S1542-3565(04)00414-8","article-title":"Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study","volume":"2","author":"Sands","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2013.08.004_bb0025","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2013.08.004_bb0030","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2013.08.004_bb0035","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/rheumatology\/kei247","article-title":"Shortening infusion times for infliximab administration","volume":"45","author":"Buch","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.crohns.2013.08.004_bb0040","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/ajg.2011.61","article-title":"Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study","volume":"106","author":"Breynaert","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2013.08.004_bb0045","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.crohns.2009.12.012","article-title":"Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study","volume":"4","author":"Van Assche","year":"2010","journal-title":"J Crohns Colitis"},{"author":"REMICADE SPC","key":"10.1016\/j.crohns.2013.08.004_bb0050"},{"key":"10.1016\/j.crohns.2013.08.004_bb0055","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.crohns.2012.03.007","article-title":"Tolerability of one hour1h 10mg\/kg infliximab infusions in patients with inflammatory bowel disease","volume":"7","author":"Babouri","year":"2012","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.crohns.2013.08.004_bb0060","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","article-title":"The incidence and management of infusion reactions to infliximab: a large center experience","volume":"98","author":"Cheifetz","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2013.08.004_bb0065","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/gut.2010.227884","article-title":"Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease","volume":"60","author":"Peyrin-Biroulet","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2013.08.004_bb0115","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/ibd.21932","article-title":"Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics","volume":"18","author":"Williet","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2013.08.004_bb0075","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ibd.21777","article-title":"Urinary tract infections in hospitalized inflammatory bowel disease patients: a 10-year experience","volume":"18","author":"Peyrin-Biroulet","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2013.08.004_bb0080","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/gut.2008.163642","article-title":"Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study","volume":"58","author":"Fidder","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2013.08.004_bb0085","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2003.017590","article-title":"Feasibility of 1hour infliximab infusions","volume":"64","author":"Van Vollenhoven","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2013.08.004_bb0120","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT study group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.crohns.2013.08.004_bb0110","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/apt.12389","article-title":"Meta-analysis: rapid infliximab infusions are safe","volume":"38","author":"Neef","year":"2013","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994613002754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994613002754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/8\/2\/161\/1617439\/8-2-161.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T01:18:27Z","timestamp":1503451107000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-lookup\/doi\/10.1016\/j.crohns.2013.08.004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S1873994613002754"],"URL":"https:\/\/doi.org\/10.1016\/j.crohns.2013.08.004","relation":{},"ISSN":["1873-9946"],"issn-type":[{"type":"print","value":"1873-9946"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolerability of one hour 10mg\/kg infliximab infusions in inflammatory bowel diseases: A prospective multicenter cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Crohn's and Colitis","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.crohns.2013.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}